MK-0524B Lipid Study (MK-0524B-063)
A Multicenter, Randomized, Double-Blind, Crossover Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT00479882, this PHASE3 trial focuses on Mixed Dyslipidemia and Primary Hypercholesterolemia and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE3
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Sep 2018 — Mar 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.